[농업경제신문 임해정 기자] Interest is growing as the World Health Organization (WHO) pays attention to three candidates for COVID-19 treatment: altesunate, imatinib, and infliximab.
The advent of the delta mutant virus has changed the course of the corona pandemic. In the United States, more than 98% of people infected with the delta mutation are infected. As a result, interest in therapeutics is on the rise.
The first candidate is Artesunate. This candidate is known as a treatment for malaria. In this clinical trial, altesunate is administered intravenously for 7 days using the recommended dose for severe malaria.
Shinpoong Pharmaceutical is one of the altesunate-related stocks. Shinpoong Pharmaceutical’s Pyramax is a fourth-generation malaria treatment selected as the primary treatment guideline for malaria in seven African countries.
The main ingredients of Pyramax tablets are known as pyronaridine and altesnate.
The second candidate is Imatinib. This candidate is an anticancer drug known as Gleevec as a treatment for myelogenous leukemia. Among domestic companies, 12 companies can make generic imatinib drugs.
Imatinib-related stocks include Ilyang Pharm, Yuyu Pharm, Korea United, Dong-A ST, Boryung Pharm, Ildong Pharm, Hanmi Pharm, Chong Kun Dang, Jeil Pharm, and Samjin Pharm.
The third candidate is infliximab. This candidate is an autoimmune treatment such as rheumatoid arthritis as a treatment for diseases of the immune system and exhibits anti-inflammatory and immunosuppressive effects. Currently, similar drugs are being produced in Korea.
Infliximab-related stocks include Aprogen MED and Celltrion. Celltrion’s Remsima is a biosimilar to Johnson & Johnson’s Remicade, which the company is developing and producing. It is used to treat autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis. It was launched in Korea in 2012 and has entered global markets such as North America, Latin America, and Europe.
“These drugs were selected in recognition of their potential to reduce the risk of death in hospitalized COVID-19 patients from an independent panel of experts,” the WHO said.
“Thousands of researchers from more than 600 hospitals in 52 countries will participate in the test,” he said.
Daewon Pharmaceutical, Curacle, Jinyang Pharmaceutical, HLB Life Science, Aminologics, Kyungdong Pharmaceutical, Myungmoon Pharmaceutical, Youngjin Pharmaceutical, Korea Pharma, Withers Pharmaceutical, CMG Pharmaceutical, Shinpoong Pharmaceutical, H. LB Pharm, Samsung Pharm, SK Bioscience, Aprogen Pharm, Woojin BNG, Hanall Biopharma, Lee Yeon Pharm, and Kukjeon Pharm recorded more than 1 million transactions.
CTC Bio, Celltrion Healthcare, Antrogen, Humasys, Jinwon Life Sciences, Seegene, Neo Immune Tech, Hwail Pharm, AB Pro Bio, Humedix, Jo-A Pharm, and Bukwang Pharm were listed in the top trading volume.
[알림] This article is for investment judgment reference only, and we are not responsible for any investment loss based on it.
By Lim Hae-jeong, staff reporter emae9031@thekpm.com
.
